Show simple item record

ACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection

dc.contributor.authorShah, Ravi
dc.contributor.authorKoupenova-Zamor, Milka
dc.contributor.authorMurthy, Venkatesh L.
dc.date2022-08-11T08:08:09.000
dc.date.accessioned2022-08-23T15:44:35Z
dc.date.available2022-08-23T15:44:35Z
dc.date.issued2020-06-05
dc.date.submitted2020-04-22
dc.identifier.citation<p>Murthy VL, Koupenova M, Shah RV. ACEing COVID-19: A Role for Angiotensin Axis Inhibition in SARS-CoV-2 Infection? Circ Res. 2020 Jun 5;126(12):1682-1684. doi: 10.1161/CIRCRESAHA.120.317174. Epub 2020 Apr 17. PMID: 32302248; PMCID: PMC7274880. <a href="https://doi.org/10.1161/CIRCRESAHA.120.317174">Link to article on publisher's site</a></p>
dc.identifier.issn0009-7330 (Linking)
dc.identifier.doi10.1161/CIRCRESAHA.120.317174
dc.identifier.pmid32302248
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27348
dc.description.abstractCardiometabolic disease, especially hypertension, is a common risk factor for mortality among individuals with SARS-CoV-2 disease (COVID-19). The role of hypertension and vascular disease in COVID-19 has raised considerable debate around how to best manage anti-hypertensive therapy to alter disease trajectory. Given the role of the ACE2 receptor in SARS-CoV-2 viral entry6, angiotensin system modulation by ACE inhibitors (ACE-I) or angiotensin-II receptor blockers (ARBs) in clinical management have taken center stage in this controversy.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32302248&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://doi.org/10.1161/circresaha.120.317174
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.subjecteditorials
dc.subjectangiotensin II
dc.subjecthypertension
dc.subjectinfections
dc.subjectCardiology
dc.subjectCardiovascular Diseases
dc.subjectImmunology and Infectious Disease
dc.subjectInfectious Disease
dc.subjectVirus Diseases
dc.titleACEing COVID-19: A Role For Angiotensin Axis Inhibition in SARS-CoV-2 infection
dc.typeEditorial
dc.source.journaltitleCirculation research
dc.source.volume126
dc.source.issue12
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/14
dc.identifier.contextkey17490178
html.description.abstract<p>Cardiometabolic disease, especially hypertension, is a common risk factor for mortality among individuals with SARS-CoV-2 disease (COVID-19). The role of hypertension and vascular disease in COVID-19 has raised considerable debate around how to best manage anti-hypertensive therapy to alter disease trajectory. Given the role of the ACE2 receptor in SARS-CoV-2 viral entry6, angiotensin system modulation by ACE inhibitors (ACE-I) or angiotensin-II receptor blockers (ARBs) in clinical management have taken center stage in this controversy.</p>
dc.identifier.submissionpathcovid19/14
dc.contributor.departmentDepartment of Medicine, Division of Cardiovascular Medicine
dc.source.pages1682-1684


This item appears in the following Collection(s)

Show simple item record